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Abstract
Coronavirus disease 2019 (COVID-19) has been spreading worldwide with a mind-boggling speed. According to a
statement from World Health Organization (WHO), COVID-19 has infected more than six billions people and caused
more than one and half million passing in the world. Based on previous experience with SARS, the Taiwanese government had decided to block viral transmission during its early stages. This review sums up the clinical characteristics,
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) viral infection process, diagnostic methods, preventive
strategy, and the executive proportions of COVID-19, as well as the name-based mask distribution system (NBMDS) in
Taiwan. We also give a review of the conceivable sub-atomic pharmacologic systems against SARS-CoV-2 specialists and
the blend of remdesivir (GS-5734), chloroquine (CQ), and hydroxychloroquine (HCQ). Lastly, we summarized the
therapeutic agents against COVID-19 as mentioned by COVID-19 treatment guidelines. In this review, development of
novel anti-SARS-CoV-2 viral agents, vaccines for COVID-19 therapy or an effective combination therapy can be expected based on all the information accumulated. Last but not least, we might want to stretch out our best respects to all
medical providers in their worldwide battle against COVID-19.
Keywords: Coronavirus disease 2019 (COVID-19), Respiratory Syndrome coronavirus 2 (SARS-CoV-2), Name-based
mask distribution system (NBMDS), Therapeutic agents, Preventive strategy

1. Introduction

C

oronavirus disease 2019 (COVID-19),
brought about by severe acute respiratory

syndrome coronavirus 2 (SARS-CoV-2) infection,
has spread worldwide with a mind-boggling
speed. According to a statement from World
Health Organization (WHO), COVID-19 has
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infected more than six billions people and caused
more than one and half million passing in the
world [1e6]. Based on previous experience with
severe acute respiratory syndrome (SARS), the
Taiwanese government had decided to block viral
transmission during its early stages. Presently,
early blockage of SARS-CoV-2 transmission has
been the key point in protecting against COVID19 [7,8]. Conﬁrmed cases in Taiwan have been
lower than those in other countries. Accordingly,
the Taiwan Center for Disease Control (TCDC)
had revealed 675 afﬁrmed cases and seven passing till the end of November 2020 (Fig. 1A). The
majority of the conﬁrmed cases were indigenous
and imported, with a peak age of 20-29 years
(Fig. 1B).
Taiwan is only 81 miles away from the coast of
China, has been constantly alert and ready to act on
potential epidemics arising from China considering
the insufferable experiences gained from the severe
acute respiratory syndrome (SARS) epidemic of 2003
[8]. Given that most patients shared nonspeciﬁc
clinical and laboratory ﬁndings, comprehensive surveillance of detailed exposure history for suspected
patients, and application of rapid detection tools are
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required. Through the combination of border control,
rapid testing and quarantine of individuals with
contact history, isolation, real-time linking of informative records with the healthcare system, and protection of health care worker safety through Trafﬁc
Control Bundling, Taiwan had been able to effectively control the COVID-19 epidemic [9,10].
We sums up the clinical characteristics, SARSCoV-2 viral life cycle and infection process, diagnostic methods, preventive strategy, and the executive proportions of COVID-19, as well as the namebased mask distribution system (NBMDS) in
Taiwan. We also give a review of the conceivable
sub-atomic pharmacologic systems against SARSCoV-2 specialists. Lastly, we summarized the therapeutic agents against COVID-19 as mentioned by
COVID-19 treatment guidelines.

2. Clinical manifestations of COVID-19
As indicated by literature reviews, fever, weariness, headache, dry cough, sputum production,
haemoptysis, sore throat, and diarrhoea have been
the most usual manifestations at the beginning of
COVID-19 infection, with other symptoms
including muscle ache, dyspnoea, productive cough,
haemoptysis, and stroke [11]. The time period of

Fig. 1. Conﬁrmed cases in Taiwan. (A) Number of conﬁrmed cases of coronavirus (COVID-19) in Taiwan till the end of November 2020. (B) The
numbers are divided into several 10-year age groups.
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symptoms onset is around 5.2 days after infection
[11]. It was reported that up to 75% of patients with
COVID-19 infection stay asymptomatic [11,12].
Around 14% of patients develop severe symptoms
and signs, including pneumonia and adult respiratory distress syndrome (ARDS), requiring hospitalization and oxygen treatment, and about 5% of
patients need intensive care and support. From
admission to intensive care unit, the time period of
length was around 10 days, while the span between
manifestation beginning and passing went from
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roughly 2 weeks to 2 months [11,13,14]. Fig. 2
revealed the symptoms of signs as COVID- 19
infection progressing.
Finding of laboratory tests incorporate raised
lactate dehydrogenase and ferritin levels. Leucopoenia and lymphopenia have been most ordinarily
noticed discoveries, while white blood cell (WBC)
counts can vary [15e17]. Findings of chest radiography and computed tomography (CT) are assorted
and vague, regularly introducing as local patchy
shadowing, bilateral patchy shadowing or multiple
ground-glass opacity lesions. As the infection advances, ground-glass opacity lesions might advance
into consolidation or crazy-paving pattern ﬁnding
(interlobular/intralobular
septal
thickening)
[18e20].

3. Diagnostic testing of the COVID-19 in
Taiwan
Diagnosis tests of COVID-19 in Taiwan were
summarized in Table 1. There are three methods
which have been popularly applied for the diagnosis
of SARS-CoV-2, including:
(1) A nucleic acid ampliﬁcation test (NAAT) by realtime reverse transcription polymerase chain reaction (rRT-PCR).
(2) Antigen test screening.
(3) Serologic and/or antibody testing.

Fig. 2. Symptoms of the COVID-19.

A nucleic acid ampliﬁcation test (NAAT) by realtime reverse transcriptase polymerase chain reaction (rRT-PCR) is the gold standard for detecting
SARS-CoV-2 infection. The speciﬁcity and sensitivity are very high. However, this method has a
window period of up to 5 days after virus exposure.

Table 1. Diagnosis of COVID-19 in Taiwan [21e24].
Types

Methods

SARS-CoV-2 commercial test system Real-time reverse transcriptase PCR (rRT-PCR)
(Roche, cobas® SARS-CoV-2).
test intended for the qualitative detection of
nucleic acids from SARS-CoV-2 in nasopharyngeal
and oropharyngeal swab samples
Rapid screening and serologic
Lateral ﬂow immunoassays
diagnosis
Time-resolved ﬂuorescence immunoassay
Hematology and biochemistry
Cell counter and biochemistry reaction Kit
examination

Nucleic Acid
Imaging technology

1. Next generation sequencing platforms (NGS)
1. Chest radiograph
2. CT images

Detection
Viral nucleic acids
FDA approved COVID-19 test Kit

Detect the presence of IgG and IgM
from whole blood, serum or plasma
1. White blood cell count <4  109/L
Lymphocyte count <1  109/L
2. C-reactive protein (CRP) level
3. Lactate dehydrogenase (LDH)
4. Aspartate aminotransferase (AST)
5. Alanine aminotransferase (ALT),
6. Creatine kinase (CK)
7. D-dimer (a ﬁbrin degradation product
present in the blood)
Viral sequence
1. Bilateral distribution of patchy shadows
2. Ground glass opacity

FDA: U.S. Food and Drug Administration; IgG: Immunoglobulin G; IgM: Immunoglobulin M; CT: computed tomography.
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Antigen tests can rapidly identify people with
SARS-CoV-2 infection with low cost, which is critical for preventing transmission. However, low accuracy is the major problem of antigen test. A
nucleic acid ampliﬁcation test (NAAT) should be
considered, if a person who is highly suspected of
SARS-CoV-2 infection with negative results of initial
antigen tests. Serologic and/or antibody testing is
not suit for diagnosing initial SARS-CoV-2 infection,
because these antibodies to SARS-CoV-2 were
merged after 21 days or more after infection. But,
the test can investigate people with prior or recent
SARS-CoV-2 infection (Fig. 3) [21e24].

4. Structure and life cycle of SARS-CoV-2
Both SARS-CoV-2 and Middle East Respiratory
Syndrome Coronavirus (MERS-CoV) have been
considered profoundly pathogenic. As shown in
Fig. 4A, the schematic structure of SARS-CoV-2
included spike proteins (S), lipid membrane, membrane proteins (M), envelope proteins (E), and
nucleocapsid protein enclosing ssRNA (N). Single
stranded RNA genome of SARS-CoV-2 was shown
in Fig. 4B [25]. The SARS-CoV-2 use their spike
proteins to bind host cell membrane receptors,
angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), for passage. Fig. 5 shows that there are eight signiﬁcant
stages of the life cycle of SARS-CoV-2. Stage 1 is that
SARS-CoV-2 enters the target cell through endocytosis or fusion after authoritative to ACE2 receptor
and TMPRSS2. The SARS-CoV-2 envelope

BioMedicine
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advances viral RNA genome discharge into the host
cell cytoplasm through fusing with the endosome
layer in the lysosomal corrosive condition. Subsequently, stage 2 is genome RNA release. The coronavirus main proteinase (3CLpro) is deciphered for
the replication of genomic RNA. From that point,
replicase polypeptide is proteolysis, delivering
helicase and RNA-dependent RNA polymerase
(RdRp) (stage 3 and 4). In stage 5, SARS-CoV-2 at
that point goes through viral RNA replication in the
host cells. In stage 6, the viral sub-genome is deciphered. Spike proteins (S), lipid membrane, membrane proteins (M), envelope proteins (E), and
nucleocapsid protein enclosing ssRNA (N) are
packaging through Golgi apparatus and the endoplasmic reticulum (stage 7). In stage 8, a novel virion
is packed and shaped by N protein and other
auxiliary proteins communicate with viral genomic
RNA. Finally, the amassed virion is then delivered
by means of exocytosis into the extracellular
compartment [11,26,27].

5. Preventive strategy of COVID-19 in Taiwan
SARS-CoV-2 infection possesses nonspeciﬁc
clinical manifestation, so that it can be easily transmitted from mild symptomatic or asymptomatic
individuals to others. As of now, avoidance of viral
passage into the human body seems to be the most
ideal choice for controlling viral spread. The Taiwan
Center for Disease Control (TCDC) has set up
specialized rules for COVID-19. Coming up next are
vital points for forestalling viral spread:

Fig. 3. Diagnostic testing of the COVID-19.
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Fig. 4. The protein structure and RNA genome of SARS-CoV-2. (A) The major structural proteins including the spike glycoprotein (S), membrane
glycoprotein (M), envelope protein (E) and Nucleocapsid Protein (N) on SARS-CoV-2. (B) Single stranded RNA genome of SARS-CoV-2.

Fig. 5. SARS-CoV-2 life cycle. Stages of the SARS-CoV-2 life cycle include virus entry, RNA release, translation, proteolysis, RNA replication and
sub-genomic transcription, translation, packaging and virion release.
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(1) Avoiding travelling to affected countries.
(2) Regular decontamination with 5% to 10% sodium hypochlorite.
(3) Social distance, including at least 1.5 m indoors
and at least 1 m outdoors.
(4) Keeping proper hygiene of individuals, such as
frequent hand washing with soap or alcoholbased hand sanitisers.
(5) Personal protective equipment, such as gloves,
eye protection, gowns and medical masks [28].
Because of the supply shortages of face masks,
The Taiwanese government has developed guidelines to protect the health and safety of the public
from the global novel coronavirus outbreak. Fig. 6
details the processing of the name-based mask
distribution system (NBMDS) in Taiwan [29]. While
medical and surgical masks should be prioritised for
health care workers, the general public can wear
cloth face masks made from household items, such
as two layers of cotton fabric, T-shirts or bedsheets.
Medical masks can ﬁlter 5-mm particles from the air
reaching the mouth/nose, reducing the transmission
of respiratory droplets to others and prevent blood
or other potentially infectious materials from
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reaching the wearer's skin, mouth or mucous
membranes. Fig. 7 summarise the medical mask
materials and associated principles [29e34]. In
addition, the structure and composition of the
different virus families occur affect their reaction to
disinfectants. Components, such as 75% ethanol
[35e38], sodium hypochlorite (1000 ppm (0.1%)10,000 ppm (1%)) [33,38,39], hypochlorous acid (10
ppm-30 ppm) [33,38e40], chlorine dioxide [40], soap
[41] and hydrogen peroxide (0.5%) [42e44] and
others [44e47] have been used to kill bacteria and
viruses. Table 2 lists the chemical formula and
preparation concentration of the disinfectants, as
well as associated principles.

6. Current therapeutic modalities for COVID19 in Taiwan, and summary of therapeutic
agents against COVID-19 as mentioned by
COVID-19 treatment guidelines
Currently, there is still lacking strong clinical evidence of existing anti-viral agents and vaccine
against SARS-CoV-2 infection. Supportive treatment is crucial, including oxygen therapy for hypoxemia and respiratory distress, intravenous ﬂuids

Fig. 6. Policies for controlling mask distribution and mask wearing to prevent viral transmission in Taiwan.
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Fig. 7. Design of the three-layer non-medical face masks for the protection of the general public against viral infection. The three-layer material is
made from pure polypropylene melt-blown polymer (middle layer), placed between two non-woven fabric layers. The outer layer is ﬂuid repellent,
while and inner layer absorbs moisture.

Table 2. Possible preventive methods of SARS-CoV-2 infection [35e38,40,44,47].
Methods

Principles

Chemical formula

Concentration

Medical mask

A medical/surgical mask help people to protect users from large
respiratory droplets of patients. Three ways of removing particles
from the airstream, such as (i) inertial impaction, (ii) diffusion, and (iii)
electrostatic attraction. This mask has three-layer materials made up
of a melt-blown polymer (most commonly polypropylene) that
prevents microbes from entering the mask A minimum of bacterial
ﬁltration efﬁciency (BFE) of the medical mask is over 95% ﬁltration
rate.
Ethanol is a volatile, ﬂammable and naturally produced through
petrochemical processes. Its effects on lipid in bacterial cell wall and
cell membrane can lead to protein denaturation.
Hypochlorous acid produced by the reaction of sodium hypochlorite
(NaClO) with carbon dioxide is a component of bleach. It is a strong
oxidant, in the form of gas or in combination with other chemicals.
Hypochlorous acid (HClO) is a weak acid from that chlorine dissolves
in water. It is the simplest oxo-acid of chlorine which is involved in
fast equilibria with oxidizers (hypochlorite, HClO and ClO) under
acidic conditions. Hypochlorous acid is effective at killing viruses.
Chlorine dioxide (ClO2) is an inorganic compound from oxygen and
chloride of two electronegative elements. This compound property
makes possible to exhibit the action as an anti-microbial agent.
They are amphiphilic: partly hydrophilic (polar) and partly
hydrophobic (non-polar). Their dual nature facilitates the mixture of
hydrophobic compounds (like oil and grease) with water. Break the oil
structure can form small fragments (emulsiﬁcation).
An oxidizing agent has the oxidizing ability. Common oxidizing
agents is hydrogen peroxide (0.5%). Oxidize cell contents to locally
inactivate.
Quaternary ammonium compounds.

Non

Non

CH3CH2OH

70%~75%

NaClO

1000 ppm (0.1%) ~
10,000 ppm (1%)

HClO

10 ppm ~30 ppm

ClO2

0.03 ppm ~0.10 ppm

Non

Non

H2O2

0.5%

Non

Non

75% ethanol

Sodium
hypochlorite
Hypochlorous
acid

Chlorine dioxide

Soap

Hydrogen
peroxide
Other
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support, and ventilator and extracorporeal membrane oxygenation therapy for patients with adult
respiratory distress syndrome (ARDS). Patients with
severe ARDS may beneﬁt from systemic corticosteroids. Supportive treatments are summarized in
Table 3 [48,49]. Currently, three clinical trials on
COVID-19 are ongoing in Taiwan (NCT 04292899,
NCT 04292730 and NCT 03808922), with remdesivir
(Veklury®) as the primary anti-SARS-CoV-2 agent.
In the one-year period since the epidemic arose,
scientists around the world made many efforts to
ﬁnd ways to prevent and treat the disease [11].

BioMedicine
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Based on the accumulating data, guidelines on
COVID-19 treatment is gradually being updated
and modiﬁed by the World Health Organization
(WHO), United States National Institutes of Health
(NIH) as well as other Health authorities [1e5].
Categorically, agents used for COVID-19 can be
roughly divided into 3 main groups (Fig. 8):
(A) Anti-viral therapy agents.
(B) Immune-based therapy agents.
(C) Adjunctive therapy agents.

Table 3. Supportive therapy for clinical conditions in COVID-19 [48,49].
Symptoms

Treatments

Targets and notes

Patients with respiratory
distress, hypoxemia
or shock

1. Give supplemental oxygen therapy
2. Initiate oxygen therapy at 5 L/min
and titrate ﬂow rate accordingly
3. Intravenous ﬂuids support

Patients with severe
ARDS

1.Ventilator support combined
with/without extracorporeal
membrane oxygenation therapy.
2. systemic corticosteroids

1. Non-pregnant patients: SpO2  90%
2. Pregnant patients: SpO2  92-95%
3. Children without emergency signs: SpO2  90%
4. Children with red ﬂag signs: SpO2  94%,
5. Patients treated with intravenous ﬂuids cautiously, and
since aggressive ﬂuid resuscitation may worsen
oxygenation
1. Chest images presented as pneumonia. Oxygenation
impairment: with the minimum level of PEEP 5cmH2O,
PaO2/FiO2 ratio 300 and > 200 is mild ARDS; PaO2/FiO2
ratio 100- 200 is moderate ARDS; PaO2/FiO2 ratio <100 is
severe ARDS.
2. Patients with severe ARDS may beneﬁt from systemic
corticosteroids.

Fig. 8. Overview of therapy agents on COVID-19.

In the latest update of NIH's guideline (updated
on Nov 18th, 2020), bamlanivimab (LY-CoV555) is
the new therapy to ﬁght against COVID-19. This
synthetic antibody-based treatment is received
Emergency Use Authorization, but NIH recommended that is not a standard care for COVID-19
[2]. It can be used for non-hospitalized patients with
mild to moderate COVID-19 and having high risk of
progressing to severe condition. Earlier, remdesivir
received approval from Europe Commission and
US-FDA, become the ﬁrst ofﬁcial drug to treat
COVID-19 [1,2]. Lopinavir/ritonavir (LPV/r; Kaletra®) and ivermectin (Stromectol®) were proposed
as potential therapeutic for COVID-19 in early 2020
[50]. However, the limited clinical improvement, no
signiﬁcant in lowering morality rate, and made
these therapeutics got recommendation against by
the guidelines, except for clinical trials. Other
treatments of anti-viral therapies can be found at
China's guideline (the latest updated on Aug 18th,
2020) with the recommendation of using chloroquine sulfate (CQ) and ribavirin (Robatrol®) combined with interferon a or lopinavir/ritonavir (LPV/
r; Kaletra®) [4,51]. Also, in this guideline, the uses of
traditional medicine were recommended for treatment of COVID-19. The distinctive, different opinions of China's guideline compared to others, and
the accomplishments in controlling disease of China
are worth to be analyzed (Table 4). However,
comprehensive clinical data on that the achievements were not published so far.
Immune-based therapies for COVID-19 are
considered as systemic treatments, using human
blood-derived products and/or immune-modulatory therapies. As of blood-derived products, those
who have recovered from SARS-CoV-2 infection
can donate their convalescent plasma or immunoglobulin to make products for treatment in other
patients [52,53]. Experimental data suggested that,
these products induce direct inhibitory effect
against SARS-CoV-2 [53]. There is not enough evidence in clinical data for blood-derived products to
be recommended by the guidelines as a standard
care treatment for COVID-19 [2,3,5]. Other therapies, such as mesenchymal stem cells, non-SARSCoV-2-speciﬁc
intravenous
immunoglobulins
(IVIG) are recommended against by experts to use
for COVID-19, except in clinical trial [2]. As of the
corticosteroids, the most recommended agent in
guidelines is dexamethasone, based on the accumulated data that showed the improvement in
clinical treatment for COVID-19 patients. However,
the guidelines recommended against the long-term
use of dexamethasone and other corticosteroids,
due to the side effects [1e5]. In addition, the
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combination of dexamethasone and remdesivir is
suggested by the NIH's guideline [2]. Other
immunmodulators (IL-1 inhibitors; anti-IL-6 receptor monoclonal antibody; Interferons a/b; Bruton's
tyrosine kinase inhibitors and Janus kinase inhibitors) are mentioned cautiously by the guidelines. Due to the lack of supportive evidence, these
products are not recommended for use in patients
with COVID-19, except in well-designed trials
[2,3,5].
Adjunctive therapy agents for use in COVID-19
course are recommended by the guidelines,
including:
(1) Anti-thrombotic therapies.
(2) Vitamin C and vitamin D.
(3) Zinc supplementation.
Because the symptoms of COVID-19 are associated with inﬂammation and a pro-thrombotic state,
anti-thrombotic agents and anti-platelet agents
were suggested as useful adjunct to COVID-19
treatment [2,5]. Recommendations for anti-thrombotic agents were given by the guidelines, such as
apixaban (Eliquis®), rivaroxaban (Xarelto®), edoxaban (Lixiana®) and dabigatran (Pradaxa®) (by the
NIH - USA) and acetylsalicylic acid (Aspirin®) (by
NCCET-Australia and NHC-China). However,
additional measures should be taken to prevent the
possible unwanted effect for certain patient groups
and risk/beneﬁt should be considered [5]. Additionally, the uses vitamin and mineral supplements
were suggested as a preventive measure for
COVID-19, as well as for attenuating the complications during course of the infection. The products of
vitamin C, vitamin D and zinc supplementations
were suggested by several studies. However, the
rationale use, beneﬁts and harms in particular
group of patients were needed further study to be
clariﬁed [1,2,5].
Please refer to the previously published article
“Approaches towards ﬁghting the COVID-19
pandemic (Review)” for molecular pharmacological
mechanisms in detail [11].

7. Introduction of synthesis methods on
remdesivir (Veklury®), chloroquine (CQ) and
hydroxychloroquine (HCQ)
Remdesivir (Compound 12) was synthesised by
Siegel et al. as illustrated in Schem 1 (Fig. 9) [54].
The iodo-based compound 1 was reacted with
Turbo Grignard reagents via metalehalogen exchange, followed by the addition of ribolactone 2 to
afford the glycosylation product 3. Treatment of 3
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Anti-viral agents for
COVID-19

Pharmacologic
mechanisms

Guidelines
WHO (Nov 20th 2020)

NIH (USA)
(Nov 18th 2020)

HCSP (France)
(Oct 19th 2020)

NHC (China)
(Aug 18th 2020)

NCCET (Australia)
(Nov 26th 2020)

Bamlanivimab (LYCoV555)

1. Targets the receptorbinding domain of the
spike protein
1. Inhibition of viral
fusion

Not mentioned

Recommended against

Not mentioned

Not mentioned

Not mentioned

Recommended against

Recommended against

Recommended against

Recommended

Recommended against

Recommended against

Recommended against

Recommended
against

Recommended
against
Recommended
against

1. Inhibition of viral
fusion
1. Inhibits RNAdependent RNA
polymerase (RpRd)

Recommended against

No recommendation

Recommended against

Recommended

Recommended against

Conditional
recommended with or
without corticosteroids

Conditional recommended

No
recommendation

Recommended against

Not mentioned

Recommended against

Not mentioned

Lopinavir/ritonavir
(Kaletra®)

1. Inhibits RNAdependent RNA
polymerase (RpRd)
1. Inhibits 3C-like
protease (3CLpro)

Recommended against

Recommended against

Recommended against

Ivermectin (Stromectol®)

1. Inhibits protease

Not mentioned

Recommended against

Not mentioned

Recommended
against
monotherapy
Not mentioned

Ribavirin (Rebetol®)

1. Inhibits RNAdependent RNA
polymerase

Not mentioned

Not mentioned

Recommended against

Chloroquine (CQ)
(Aralan®)
Hydroxychloroquine
(HCQ)
(Plaquenil®)
Umifenovir (Arbidol®)
Remdesivir (GS-5734;
Veklury®)

Favipiravir (Avigan®)

Recommended to
use with interferon
a or lopinavir/
ritonavir

Recommended
against
Conditional
recommended for
patients require
oxygen but not
ventilation
Recommended
against
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Table 4. Summary of anti-viral agents against SARS-CoV-2 of COVID-19 by guidelines.

Recommended
against
Recommended
against
Not mentioned

Abbreviations: WHO: World Health Organization; NIH: United States National Institutes of Health; HCSP: Haut Conseil de la sant
e publique; NHC: China's National Health
Commission; NCCET: Australian National COVID-19 Clinical Evidence Taskforce.
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Fig. 9. Synthesis of remdesivir.

with TMSCN, TMSOTf and TfOH at 78  C afforded 4, which yielded benzyl deprotection product 5
after reacting with BCl3. Acetonide protection of the
20 ,30 -hydroxyl moieties with 2,2-dimethoxypropane
in the presence of H2SO4 afforded 6. 2-Ethyl-1butanol 7 and L-alanine 8 were treated with HCl(g)
to generate ester product 9, which was reacted with
OP(OPh)Cl2 under base conditions, followed by 4nitrophenol to obtain the p-nitrophenolate 2-ethylbutyl-L-alaninate prodrug precursor 10. The
coupling reaction between 6 and 10 under MgCl2
generated 11, after which in situ acetonide deprotection was performed through concentrated HCl to
afford target molecule remdesivir (Compound 12).
Molecular docking of remdesivir binding to the
RNA-dependent RNA polymerase (RdRp) was

shown on Supplementary video S1 (https://youtu.
be/s_SUUMO7URw).
As shown in Fig. 10, chloroquine (Compound 25)
was synthesised by Drake N. L. et al. and Price Ch.
C. et al. as described in Schem 2 [55,56]. Accordingly, 4,7-Dichloroquinoline 19 was prepared from
3-chloroaniline 13 via 1,4-addition with ethoxymethylenmalonic acid 14, thermal heterocyclisation, hydrolysis, decarboxylation and POCl3
chlorination. Novaldiamine 24 was synthesised
following three steps. Acetoacetic ester 20 alkylation
with 2-diethylaminoethylchloride 21 generated 2diethylaminoethylacetoacetic acid ester 22, which
yielded 1-diethylamino-4-pentanone 23 upon acidic
hydrolysis using hydrochloric acid and simultaneous decarboxylation. Reductive amination of this
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Fig. 10. Synthesis of chloroquine (CQ).

compound with hydrogen and ammonia using
Raney nickel as a catalyst yielded 24. Nucleophilic
aromatic substitution of chlorine at C-4 in 19 with
novaldiamine 24 generated the desired molecule
chloroquine 25.
Finally, we provide two methods (pathways) for
the synthesis of chloroquine (CQ) by Synthia
Organic Retrosynthesis Software (Merck, Taiwan) in
the Supplementary document.

8. Concluding and remarks
This review describes several clinical manifestations of COVID-19, analyses the SARS-CoV-2
genome and outlines the life cycle of SARS-CoV-2.
Several methods have been used to examine SARSCoV-2 infections. The Taiwanese government has
established several policies for controlling viral
spread. Last but not least, we summarized the
therapeutic agents against COVID-19 as mentioned
by COVID-19 treatment guidelines.

To avoid direct contact with suspected COVID-19
cases, viral secretions and infected droplets, the
following relevant preventive measures should be
followed:
(1) Pay attention to and cooperate with the latest
epidemic prevention policies issued by the
government.
(2) Maintain hand hygiene habits, particularly
avoiding touching the eyes, nose and mouth
with unclean hands.
(3) Maintain social distancing or wear masks, avoid
crowded public places and taking public
transportation.
(4) Reduce hospital visits except for urgent medical
needs.
(5) Comply with relevant regulations if home
quarantined or in isolation.
(6) Stop working or going to school when sick.

(7) Inform your medical providers about your travel
history, contact history, occupation and cluster
history.
We expect Taiwan to globally interact and cooperate with other countries to develop rapid and accurate screening assays, produce vaccines, design
novel agents against SARS-CoV-2 and reduce the
side effects. Ultimately, our long-term goal is to be
free from COVID-19.
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1. Analysis parameters
Analysis type: Automatic Retrosynthesis
Rules: none selected
Filters: Cut All Heterocycles, Strategies
Max. paths returned: 50
Max. iterations: 1000
Buyable:
1. Max. molecular weight - 1000 g/mol
2. Max. price - 1000 $/g
Known:
1. Max. molecular weight - 1000 g/mol
2. Min. popularity - 25
Inventory:
1. Max. molecular weight - 1000 g/mol
Shorter paths: no
Pathway linearity: COMBO
Protecting groups: LESS
Reaction
scoring
formula:
20þ1000000*(FILTERSþCONFLICTþNON_SELECTIVITY)þ40*PROTECT
Chemical
scoring
formula:
SMALLER^3,
SMALLER^1.5
Min. search width: 100
Max. reactions per product: 20

2. Paths
2 paths found. Paths are sorted by score. Reactions are
sorted in appearance order for each path.
2.1. Path 1
Score: 58.79

Supplementary document. Paths of analysis*
Analysis 2892
Synthia

Figure 1. Outline of path 1.

*
The results stated herein were generated using the proprietary platform owned and maintained by Grzybowski Scientiﬁc Inventions, Inc., a subsidiary
of Merck KGaA, Darmstadt Germany. The results are provided on an as is basis, and shall be used solely in connection with the rights afforded in the
license agreement and for no other purpose.
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2.1.1. Synthesis of quinolones

Substrates:
Substrates:
1. formamide e available at Sigma-Aldrich
2. 2-brom-4-chlor-acetophenon e available at
Sigma-Aldrich

1. n4,n4-diaethyl-1-methyl-butandiyldiamin e
available at Sigma-Aldrich
2. 7-chloro-quinolin-4-ol e available at SigmaAldrich
Products:

Products:
1. 7-chloro-quinolin-4-ol e available at SigmaAldrich
Typical
conditions:
[Pd]
or
[Cu].Cs2CO3.NaOtBu.dioxane
Protections: none
Yield: good
Reference: 10.1055/s-0030-1260198 AND 10.1021/
jo701384n AND 10.1021/ol800837z
Retrosynthesis ID: 12281

1. (-)-chloroquine e available at Sigma-Aldrich
Typical conditions: 1.PCl5.2.amine
Protections: none
Yield: good
Reference: 10.1021/jm300780p AND 10.3390/
molecules170910902 AND 10.1021/jm00392a017
Retrosynthesis ID: 14885
2.2. Path 2
Score: 117.57

2.1.2 Amination of pyridones

Figure 2. Outline of path 2.
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2.2.1. Synthesis of quinolones

Substrates:
1. formamide e available at Sigma-Aldrich
2. 2-brom-4-ﬂuor-acetophenon e available at
Sigma-Aldrich
Products:
1. 7-ﬂuoro-quinolin-4-ol e available at SigmaAldrich
Typical
conditions:
[Pd]
or
[Cu].Cs2CO3.NaOtBu.dioxane
Protections: none
Yield: good
Reference: 10.1055/s-0030-1260198 AND 10.1021/
jo701384n AND 10.1021/ol800837z
Retrosynthesis ID: 12281
2.2.2. Nucleophilic aromatic substitution

Substrates:
1. 7-ﬂuoro-quinolin-4-ol e available at SigmaAldrich
Products:
1. 7-amino-quinolin-4-ol e available at SigmaAldrich
Typical conditions: Solvent
Protections: none
Yield: good
Reference: 10.1002/9781118093559.ch4
Retrosynthesis ID: 49478
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2.2.3. Sandmeyer Reaction

Substrates:
Substrates:
1. 7-amino-quinolin-4-ol e available at SigmaAldrich
Products:
1. 7-chloro-quinolin-4-ol e available at SigmaAldrich
Typical
conditions:
t-BuONO.CuCl2
or
TMSCl.MeCN.reﬂux or NaNO2.Hcl.CuCl
Protections: none
Yield: moderate
Reference: DOI: 10.1016/j.ejmech.2013.01.046 and
10.1021/jm040185a
and
10.1021/acs.jmedchem.
5b00152 and 10.1021/ja066472g (SI, page S14) and
10.1021/jm3012273 and 10.1002/ejoc.201001395 and
10.1002/ejic.201501400 and 10.1016/j.bmcl.2011.08.
073
Retrosynthesis ID: 29905
2.2.4. Amination of pyridones

1. n4,n4-diaethyl-1-methyl-butandiyldiamin e
available at Sigma-Aldrich
2. 7-chloro-quinolin-4-ol e available at SigmaAldrich
Products:
1. (-)-chloroquine e available at Sigma-Aldrich
Typical conditions: 1.PCl5.2.amine
Protections: none
Yield: good
Reference: 10.1021/jm300780p AND 10.3390/
molecules170910902 AND 10.1021/jm00392a017
Retrosynthesis ID: 14885
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